Product Information:

GABICA CR 165mg Tablets contain Pregabalin 165mg in a controlled-release (CR) formulation. Pregabalin is a gamma-aminobutyric acid (GABA) analog that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters involved in pain signaling, seizure activity, and anxiety.

The controlled-release design allows for once-daily dosing, providing steady drug levels over 24 hours, which may improve tolerability and adherence compared to immediate-release formulations.

⚠️ Note: The 165mg strength is specifically designed for once-daily dosing and is not interchangeable with immediate-release pregabalin on a mg-per-mg basis.

Uses of (GABICA CR 165MG TABLETS):

1. Management of neuropathic pain (e.g., diabetic peripheral neuropathy, postherpetic neuralgia)
2. Adjunctive therapy in partial-onset seizures in adults
3. Off-label use in generalized anxiety disorder (GAD) (in select cases)

Key Benefits of (GABICA CR 165MG TABLETS):

1. Once-daily dosing improves convenience and compliance
2. Smoother plasma concentration reduces peak-related side effects (e.g., dizziness, drowsiness)
3. Effective for long-term maintenance therapy
4. Lower risk of missed doses compared to multiple daily doses

How To Use (GABICA CR 165MG TABLETS):

1. Take once daily, preferably after an evening meal (food enhances absorption).
2. Swallow whole with water—do not crush, chew, split, or dissolve (doing so destroys the controlled-release mechanism and may cause dose dumping).
3. Take at the same time each day.
4. Do not stop abruptly—taper gradually under medical supervision to avoid withdrawal symptoms (insomnia, headache, nausea, seizures).

When Not to Use (GABICA CR 165MG TABLETS):

Do not use if you have:

1. Hypersensitivity to pregabalin or any excipients
2. History of angioedema with pregabalin
3. Severe renal impairment (CrCl <30 mL/min)—dose adjustment or alternative formulation required
4. Pregnancy or breastfeeding (unless clearly needed after risk-benefit assessment)

Side Effects of (GABICA CR 165MG TABLETS):

Common: Dizziness, somnolence (drowsiness), dry mouth, peripheral edema (swelling in legs/feet), weight gain, blurred vision.

Rare: Fatigue, difficulty concentrating, mood changes.

Serious (rare):

1. Angioedema (facial, lip, or throat swelling—seek emergency care)
2. Suicidal thoughts or behavior (monitor for new or worsening depression)
3. Rhabdomyolysis (muscle pain, weakness, dark urine)
4. Discontinue and seek medical help if severe reactions occur.

Dosage: (GABICA CR 165MG TABLETS):

1. Starting dose: 165mg once daily (evening)
2. May be increased after 1 week to 330mg once daily (max 330mg/day for CR formulation)
3. Renal impairment: Avoid if CrCl <30 mL/min; use immediate-release with dose adjustment if needed
4. Elderly: Start at 165mg once daily; monitor for sedation and falls

Who It’s For (GABICA CR 165MG TABLETS):

Adults with chronic neuropathic pain or epilepsy who require simplified, once-daily therapy and have responded to initial pregabalin treatment. Not for acute pain or treatment-naïve patients without titration.

Warnings & Precautions:

1. May impair driving or operating machinery—avoid until effects are known
2. Monitor for weight gain, edema, and psychiatric symptoms
3. Use cautiously in patients with heart failure or diabetes
4. Risk of misuse or dependence—prescribe responsibly
5. Not bioequivalent to immediate-release pregabalin—do not substitute without medical supervision

Drug Interactions:

1. CNS depressants (opioids, benzodiazepines, alcohol): Additive sedation and respiratory depression
2. ACE inhibitors: Possible increased risk of angioedema
3. Thiazolidinediones (e.g., pioglitazone): May worsen fluid retention
4. Always inform your doctor about all medications.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date on the blister pack. Available by prescription in Pakistan.